#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	18198	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2429	914.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1558	1558	C	1188	C,G	1187,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	18198	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2429	914.5	0	HET	.	.	.	A69G	.	69	69	A	443	443	A	1151	A,G	897,254	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31396	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4132	946.1	0	.	n	.	0	T695C	SNP	695	695	T	1368	1368	C	1119	C,A,T	1116,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31396	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4132	946.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	2010	2010	A	1269	A,C	1267,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31396	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4132	946.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2644	2644	C	1134	C,T,G	1130,2,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31396	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4132	946.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2718	2718	A	1021	A,T	1019,2	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31396	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4132	946.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	3270	3270	C	1165	C,G,A	1160,3,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	2564	folP	855	855	100.0	folP.l15.c4.ctg.1	2000	159.6	1	SNP	p	R229S	1	.	.	685	687	AGC	1280	1282	AGC	252;251;254	A,T;G;C	250,1;251;254	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6394	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3927	203.0	1	SNP	p	S91F	1	.	.	271	273	TTC	844	846	TTC	267;269;266	T;T;C,T	267;269;265,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6394	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3927	203.0	1	SNP	p	D95G	1	.	.	283	285	GGC	856	858	GGC	260;259;259	G;G,A;C	260;258,1;259	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6394	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3927	203.0	1	SNP	p	G95N	0	.	.	283	285	GGC	856	858	GGC	260;259;259	G;G,A;C	260;258,1;259	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	2498	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1840	169.0	1	SNP	p	G45D	0	.	.	133	135	GGC	734	736	GGC	294;297;299	G;G,T;C	294;296,1;299	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1442	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c30.ctg.1	1496	119.9	0	.	n	.	0	A197.	DEL	197	197	A	878	878	A	263	A	263	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6342	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3493	225.9	1	SNP	p	D86N	0	.	.	256	258	GAC	906	908	GAC	297;296;296	G;A,C;C,T,G	296;293,1;292,2,1	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6342	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3493	225.9	1	SNP	p	R87W	0	.	.	259	261	CGT	909	911	CGT	294;292;292	C;G;T,C	293;291;290,1	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6342	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3493	225.9	1	SNP	p	S87R	1	.	.	259	261	CGT	909	911	CGT	294;292;292	C;G;T,C	293;291;290,1	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6342	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3493	225.9	1	SNP	p	R87I	0	.	.	259	261	CGT	909	911	CGT	294;292;292	C;G;T,C	293;291;290,1	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6342	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3493	225.9	1	SNP	p	S88P	0	.	.	262	264	TCC	912	914	TCC	293;295;297	T;C;C	293;294;296	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5326	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3025	219.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1763	1765	GGC	308;304;307	G;G;C,G	308;304;306,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	5062	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2866	219.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1501	1503	GCA	287;289;293	G;C,T;A,C	287;288,1;292,1	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5062	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2866	219.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1504	1506	ATC	292;290;291	A;T,C;C	292;289,1;291	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5062	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2866	219.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1516	1518	GTG	293;293;289	G;T;G,A	293;293;288,1	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5062	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2866	219.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1516	1518	GTG	293;293;289	G;T;G,A	293;293;288,1	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5062	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2866	219.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2020	2022	ACC	254;259;257	A;C;C,T	254;259;256,1	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5062	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2866	219.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2074	2076	GCG	275;275;275	G,A;C;G,A	274,1;275;274,1	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5062	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2866	219.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2074	2076	GCG	275;275;275	G,A;C;G,A	274,1;275;274,1	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5062	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2866	219.5	1	SNP	p	G543S	1	.	.	1627	1629	AGC	2197	2199	AGC	294;294;294	A;G;C,G	294;294;293,1	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5062	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2866	219.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2206	2208	GGC	277;275;278	G;G,C;C	277;274,1;278	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5062	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2866	219.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2224	2226	CCG	281;284;286	C;C,A;G,T,C	279;281,1;282,1,1	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6932	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3632	237.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1911	1913	CCG	299;298;301	C,G;C;G,A,C	297,2;298;299,1,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2882	porA	1146	1146	99.91	porA.l15.c4.ctg.1	2372	151.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	872	872	C	213	C,G	212,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	400	porB1a	984	104	93.27	porB1a.l15.c17.ctg.2	254	55.6	0	.	p	.	0	M18T	NONSYN	52	54	ATG	133	135	ACG	90;88;85	A;C;G	90;88;85	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	400	porB1a	984	104	93.27	porB1a.l15.c17.ctg.2	254	55.6	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	175	177	CAA	29;24;20	C;A;A	29;24;20	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	400	porB1a	984	104	93.27	porB1a.l15.c17.ctg.2	254	55.6	0	.	p	.	0	S34Y	NONSYN	100	102	TCC	181	183	TAC	11;7;1	T;A;C	11;7;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	400	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	253	41.1	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	25;30;35	T;T;A	25;30;35	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	400	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	253	41.1	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	79;79;79	C;A;T	79;79;79	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	400	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	253	41.1	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	79;79;79	A;G;T	79;79;79	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	400	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	253	41.1	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	79;79;79	T;A,C;C,G	79;78,1;78,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	400	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	253	41.1	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	1;1;1	G;C;A	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	400	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	253	41.1	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	1;1;1	G;C;A	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	400	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	253	41.1	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	1;1;2	G;A;C	1;1;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	400	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	253	41.1	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	2;2;2	A;T;C	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	400	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	253	41.1	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	3;3;3	T;C;G	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	400	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	253	41.1	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	3;4;4	G;C;C	3;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	400	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	253	41.1	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	4;4;4	A;G;C	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	400	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	253	41.1	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	5;6;6	G;C;C	5;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	400	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	253	41.1	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	6;6;6	G;T;T	6;6;6	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3690	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1881	242.2	0	.	p	.	0	N38E	NONSYN	112	114	AAT	589	591	GAA	315;317;317	G;A,G;A	315;316,1;317	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3690	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1881	242.2	0	.	p	.	0	N134D	NONSYN	400	402	AAT	877	879	GAT	310;311;312	G,T;A,C;T	309,1;310,1;312	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3690	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1881	242.2	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1000	1002	TCA	337;336;338	T;C;A	337;336;338	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3690	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1881	242.2	0	.	p	.	0	Y216H	NONSYN	646	648	TAT	1123	1125	CAT	289;289;288	C;A;T	289;289;288	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3690	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1881	242.2	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1129	1131	GTC	282;285;283	G;T;C	282;285;283	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3690	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1881	242.2	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1141	1143	TCT	280;279;277	T,G;C;T	279,1;279;277	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3690	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1881	242.2	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1459	1461	GCA	287;289;289	G;C,T;A	287;288,1;289	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3690	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1881	242.2	1	SNP	p	G120K	1	.	.	358	360	AAG	835	837	AAG	311;311;317	A;A;G,T	310;310;315,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3690	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1881	242.2	1	SNP	p	A121D	1	.	.	361	363	GAC	838	840	GAC	319;316;316	G,A;A;C	317,1;315;316	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3690	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1881	242.2	1	SNP	p	D121N	0	.	.	361	363	GAC	838	840	GAC	319;316;316	G,A;A;C	317,1;315;316	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	12186	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5310	285.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1726	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1549	138.8	1	SNP	p	V57M	1	.	.	169	171	ATG	762	764	ATG	324;323;316	A;T;G	324;323;316	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
